Skip to main content
. 2015 May 22;9:2745–2756. doi: 10.2147/DDDT.S84070

Table 1.

Composition of the formulations (F1 and F2) developed in this study

Component F1 F2
SP 70% 60%
TPGS 0% 10%
VST 30% 30%

Abbreviations: SP, Soluplus; TPGS, D-alpha-tocopherol polyethylene glycol 1000 succinate; VST, valsartan; F1 and F2, solid dispersion formulations used in this study.